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The occupancy of high-affinity ryanodine-binding sites of isolated heavy sarcoplasmic reticulum vesicles oc- 
curring in concentrated salt solutions affects ATP-dependent calcium accumulation and caffeine-induced 
calcium release. The initial suppression of calcium uptake is followed by a marked uptake activation result- 
ing in a reduction of the final calcium level in the medium. Simultaneously, caffeine-induced calcium release 
is blocked. The dependence of inhibition of calcium uptake and caffeine-induced calcium release observed 
in assay media containing physiological concentrations of magnesium and ATP on the concentration of 
ryanodine corresponds to the drug’s effectiveness in living muscles. 
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1. INTRODUCTION 
Indirect evidence has been provided in numerous 
studies indicating that ryanodine might interfere 
with muscle function as a result of its effect on the 
muscles’ sarcoplasmic reticulum calcium transport 
system [l-7]. This notion has been pursued al- 
though the drug concentrations which affect sarco- 
plasmic reticulum calcium transport in vitro are 
several orders of magnitude higher than those af- 
fecting living muscles [1,2,8,9]. A further com- 
plication in comparing the drug’s action in vivo 
and in vitro is the complexity of its effects. In vitro 
calcium uptake of and/or calcium release from 
isolated sarcoplasmic reticulum vesicles can be en- 
hanced or reduced by ryanodine [2,4,6]. In vivo 
ryanodine might cause contractures or reduce 
forced development depending on the animal 
species and/or muscle type [ 10-121. Part of the ap- 
parently controversial findings might be due to the 
selected experimental conditions. Thus, observa- 
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tions made in media containing neither magnesium 
nor ATP are difficult to relate to in vivo observa- 
tions [1,6,7]. Most recently, in a series of papers 
starting with the report of Pessah et al. [13], 
ryanodine has been used successfully as a high- 
affinity label for protein components in the sar- 
coplasmic reticulum associated with structures 
supposedly involved in calcium release [ 13-161. As 
an essential modification Pessah et al. [14] in- 
troduced the application of high salt concentra- 
tions to favour high-affinity ryanodine binding. 
The reported concentrations at which ryanodine is 
bound by the isolated membranes are similar to 
those which are effective in vivo. Here, it will be 
shown that by applying high salt concentrations 
ryanodine affects ATP-supported calcium uptake 
by isolated sarcoplasmic reticulum vesicles as well 
as the release of calcium from these preparations at 
concentrations of the drug comparable to those 
previously reported for living muscles. 
2. MATERIALS AND METHODS 
Heavy sarcoplasmic reticulum vesicles were 
prepared from predominantly white rabbit hind leg 
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muscles according to Hasselbach and Makinose 
[17] by treating 100 g minced muscle for 4 x 30 s 
in 400 ml extraction fluid containing 0.1 M KCl, 
5 mM potassium phosphate (pH 7.0), 2 mM 
EDTA, 0.1 mM phenylmethylsulfonyl fluoride in 
a mixer at 4°C. Myofibriles were removed from 
the suspension by centrifugation in a Sorval GS3 
rotor at 5000 rpm for 30 min. The heavy vesicles 
were separated from the supernatant by subse- 
quent centrifugation in a Spinco type 19 rotor at 
10000 rpm for 30 min. Contaminating contractile 
proteins were extracted by treating the pellet with 
10 vols of 0.6 M KCI, 0.3 M sucrose, 3.0 mM 
ATP, 3.0 mM MgCl2, 0.1 mM benzethonium-Cl 
and 0.1 mM benzamidine-HCl, 0.1 PM dithio- 
threitol for 20 min. Subsequently the vesicles were 
sedimented by centrifugation in a Spinco rotor Ti 
60 at 55 000 rpm for 45 min and resuspended in 
0.1 M KC1 (30-50 mg/ml). 
Calcium uptake and release experiments were 
performed as described by Su and Hasselbach [ 181. 
The standard medium contained 50 mM potassium 
gluconate, 50 mM KCI, 100 mM sucrose, 50 mM 
imidazole sulfate (pH 7.0), 2 mM ATP, 8 mM 
phosphoenofpyruvate, 0.04 mg/ml phosphoenol- 
pyruvate kinase, 3.0 mM magnesium gluconate, 
20 PM 45CaC12 ( - 20000 cpm/ml). Calcium up- 
take was started by adding 0.2 mg/ml vesicles to 
15 ml of the assay solution. Aliquots were taken at 
appropriate time intervals and filtered through a 
glass nitrocellulose filter combination (Schleicher 
& Schuell, GF 9 glass filter and BA 85 nitrocellu- 
lose filter, 0.45 pm). Calcium release was initiated 
by adding 10 mM caffeine or 0.1 mM quercetin, 
final concentrations. 45Ca was determined by 
liquid scintillation counting of the filtrate. 
Ryanodine treatment of the vesicles was performed 
at a protein concentration of 10 mg/ml in 0.6 M 
KCl, 10 mM imidazole sulfate (pH 7.0) at room 
temperature (20°C). 
3. RESULTS 
Increasing amounts of ryanodine are added to 
standard calcium uptake media, before the reac- 
tion is started by the addition of ATP; the final 
drug concentration in the assays must exceed 
1OOpM in order to affect calcium uptake. As 
shown in fig.la, the initial rate of calcium uptake 
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Fig.1. Effect of ryanodine on ATP-supported calcium 
uptake and caffeine-induced calcium release. (a) The 
assay solution described in section 2 contained 3OOpM 
ryanodine. (b) 10 mg/ml vesicles were incubated for 
30 min in 0.6 M KC1 containing 1 /IM ryanodine at 20°C 
prior to the start of the reaction. The total ryanodine 
concentration in the assay was 30 nM. Calcium release 
was induced by the addition of 10 mM caffeine at 
10 min as shown by the arrows. (0) Calcium uptake and 
release without ryanodine. (m) Calcium uptake and 
release in the presence of ryanodine. 
is considerably retarded by 300 ,uM ryanodine as 
compared to that in the control. Yet after approx. 
5 min calcium uptake starts to be accelerated, sur- 
passing control uptake and terminating at a calci- 
um level significantly lower than that reached in 
the controls. Likewise, ryanodine concentrations 
higher than 100pM are needed to suppress 
caffeine-induced calcium release. This blockage of 
calcium release by ryanodine does not occur when 
the drug is added l-5 min before the releasing 
agent. Calcium release induced by 0.1 mM 
quercetin is abolished by ryanodine under the same 
experimental conditions as described for caffeine 
(not shown). 
In agreement with the reported enhancement of 
ryanodine binding to sarcoplasmic reticulum prep- 
arations in the presence of high salt concentra- 
tions, incubation of the preparation with the drug 
in high salt media greatly increases the prepara- 
tion’s drug sensitivity. Fig. 1 b illustrates the same 
experimental arrangement as shown in fig.la, ex- 
cept following an incubation of 10 mg/ml of the 
vesicular preparation with 1.0 ,uM ryanodine in 
0.6 M KC1 for 30 min. After dilution of the vesicu- 
lar suspension SO-fold into the reaction medium to 
0.2 mg protein/ml and nominally 0.02 PM 
ryanodine, calcium uptake and caffeine-induced 
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calcium release are inhibited as observed with 
300pM ryanodine at low salt concentrations: the 
initial inhibition of calcium uptake is followed by 
a significantly improved calcium-concentrating 
ability of the preparation and the abolition of 
caffeine-induced calcium release. Since calcium 
uptake and release experiments were performed at 
low salt concentration and last 30 min, time- 
dependent change of the high salt induced drug 
binding could occur. We have therefore suspended 
the high salt pretreated preparation in low salt up- 
take media and started the reaction by adding ATP 
after 30 min. No change in the activity pattern 
could be detected following this treatment, largely 
excluding time-dependent dissociation of the agent 
from its receptor in the uptake release assay. Figs 
2 and 3 show that the inhibition of the initial calci- 
um uptake and of caffeine-induced calcium release 
exhibit a similar concentration dependence. When 
the vesicles were treated with ryanodine in the high 
salt medium, an incubation time of 30 min is just 
sufficient for 1 PM ryanodine to reduce calcium 
release induced by 10 mM caffeine completely. 
Both reactions, calcium uptake and caffeine- 
oh 1 
0.03 0.1 0.3 1 10 
RYANODINE ,,M 
Fig.2. Dependence of inhibition of the rate of calcium 
uptake on the concentration of ryanodine. The rates 
were obtained from the amount of calcium taken up dur- 
ing the incubation period of 1 min. Under control condi- 
tions 70% of the added calcium (20 PM) was taken up by 
native vesicles and taken as 100%. Calcium uptake can- 
not reliably be terminated at shorter time intervals by the 
applied filtration method. The ryanodine concentrations 
given on the abscissa are those present in the 0.6 M KCI 
solution in which 10 mg/ml vesicles were incubated for 
30 min at 20°C prior to addition to the uptake medium. 
(0) Rate of uptake, vertical bars, SE; n = 3-5; (0) dif- 
ference between the rate of uptake in the absence and 
presence of 10,~M ryanodine - taken as 100%. 
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Fig.3. Dependence of inhibition of caffeine-induced cal- 
cium release from actively loaded vesicles on the concen- 
tration of ryanodine. Prior to the start of the reaction 
the vesicles were incubated for 30 min in 0.6 M KC1 with 
or without ryanodine at the concentrations indicated on 
the abscissa. The vesicles were loaded for 10 min with 
80-95 nmol/mg calcium. Caffeine-induced calcium 
release was initiated by the addition of 10 mM caffeine 
final concentration. The quantity of calcium released 
after 15 s was taken as measure of the releasing action 
of caffeine. 30 nmol/mg calcium were released from 
control vesicles and set as 100%. Vertical bars, SE; 
n = 4. 
induced calcium release, are half-maximally af- 
fected at 0.15-0.2 PM ryanodine in the incubation 
medium. The abolition of caffeine-induced release 
indicates that the release competent vesicle fraction 
present in our preparations is completely inhibited 
by ryanodine. On the other hand, the uptake rate 
is maximally reduced by 70%. Calcium uptake of 
approx. 30% of the preparation is not affected by 
ryanodine or is ryanodine-insensitive. 
4.DISCUSSION 
Our results show that ryanodine can affect ATP- 
supported calcium uptake of and calcium release 
from isolated sarcoplasmic reticulum membranes 
at submicromolar concentrations. Thus, the drug 
interferes with the functions of the sarcoplasmic 
reticulum in the same concentration range as it af- 
fects muscle function in vivo [8,9,1 I]. 
The increase in effectiveness of the drug under 
conditions comparable to those prevailing in living 
muscles has been accomplished by treating the 
preparations with the drug at high salt concentra- 
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tions [14-161. The reported dissociation constants 
[15,16] agree well with the concentration range 
where the drug affects calcium uptake and 
caffeine-induced calcium release. As observed pre- 
viously, the drug appears to produce two oppos- 
ing, subsequently occurring changes in the 
membrane properties [6]. The initial calcium up- 
take inhibition is followed by an uptake activation. 
A modulation of the calcium pump activity by 
ryanodine which could cause this activity pattern 
can largely be excluded since the calcium transport 
ATPase is not affected by the drug [1,4]. Hence 
the drug’s effects on the calcium permeability of 
the membranes should be responsible for the com- 
plex pattern of calcium uptake. At first, the perme- 
ability of the membrane must be increased by the 
drug. Subsequently, the apparent leak must be 
closed, resulting in diminished passive calcium ef- 
flux. In this state caffeine and quercetin have 
become ineffective as calcium-releasing agents. 
The two opposing effects presumably originate 
from the same drug-protein complex. Since a cor- 
responding transition of the properties of the 
membranes is observed at low and high concentra- 
tions of the drug in the incubation medium it is 
unlikely that minor ryanodine derivatives, present 
in the preparation, might give rise to this com- 
plicated action profile [21]. It should be stressed 
that opposing permeability changes occur in the 
presence of physiological magnesium and ATP 
concentrations. In contrast, in the absence of 
ATP, millimolar concentrations of magnesium 
suppress the action of the drug on actively and 
passively loaded preparations [ 1,6,7]. 
The question as to how the transition from the 
high- to low-permeability state might occur during 
ATP-supported calcium uptake is difficult to ap- 
proach. Similar biphasic reaction patterns have 
repeatedly been described [22-251, but no generally 
accepted explanation has been found. Another 
feature of the vesicular preparation which could be 
related to the observed biphasic uptake pattern is 
its inhomogeneity. All preparations contain two 
subpopulations of vesicles [5,6,18], since it is 
rather difficult to achieve a complete separation of 
the two populations. Both fractions can pump cal- 
cium, but only one is equipped with the calcium- 
release channels. The latter is unable to store calci- 
um when its channels are open. If the state of the 
calcium-release channel, open or closed, depends 
122 
on the concentration of calcium in the surrounding 
medium, as assumed to explain calcium-induced 
calcium release [26,27], calcium depletion by the 
release incompetent fraction might result in the 
closure of the calcium-release structure of the 
release competent fraction. As a consequence, this 
fraction would start to take up calcium giving rise 
to the second uptake period. If this mechanism 
were relevant, a second uptake phase would always 
start at the same degree of calcium depletion of the 
medium. At variance with this assumption, it 
proves however to be impossible to induce the 
second uptake phase by the addition of the uptake 
assay of a small amount of EGTA to lower the 
calcium level. A further difficulty opposing this ex- 
planation resides in the finding that quite often flat 
shoulders of variable length separate the initial and 
final more rapid uptake periods. This suggests that 
the calcium-release channel is closed by a process 
depending only on time. 
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